GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » EV-to-EBIT

Zeo ScientifiX (Zeo ScientifiX) EV-to-EBIT : 0.47 (As of May. 01, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zeo ScientifiX's Enterprise Value is $-474 Mil. Zeo ScientifiX's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was $-1,017 Mil. Therefore, Zeo ScientifiX's EV-to-EBIT for today is 0.47.

The historical rank and industry rank for Zeo ScientifiX's EV-to-EBIT or its related term are showing as below:

ZEOX' s EV-to-EBIT Range Over the Past 10 Years
Min: -3346.46   Med: -6.48   Max: 0.47
Current: 0.47

During the past 13 years, the highest EV-to-EBIT of Zeo ScientifiX was 0.47. The lowest was -3346.46. And the median was -6.48.

ZEOX's EV-to-EBIT is ranked better than
77.95% of 440 companies
in the Biotechnology industry
Industry Median: 8.725 vs ZEOX: 0.47

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Zeo ScientifiX's Enterprise Value for the quarter that ended in Jan. 2024 was $-474 Mil. Zeo ScientifiX's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was $-1,017 Mil. Zeo ScientifiX's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was 214.55%.


Zeo ScientifiX EV-to-EBIT Historical Data

The historical data trend for Zeo ScientifiX's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zeo ScientifiX EV-to-EBIT Chart

Zeo ScientifiX Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.54 -12.42 -5.49 -4.41 -1.80

Zeo ScientifiX Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -1.80 0.47

Competitive Comparison of Zeo ScientifiX's EV-to-EBIT

For the Biotechnology subindustry, Zeo ScientifiX's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zeo ScientifiX's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zeo ScientifiX's EV-to-EBIT falls into.



Zeo ScientifiX EV-to-EBIT Calculation

Zeo ScientifiX's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-474.343/-1017.329
=0.47

Zeo ScientifiX's current Enterprise Value is $-474 Mil.
Zeo ScientifiX's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,017 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zeo ScientifiX  (OTCPK:ZEOX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Zeo ScientifiX's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jan. 2024 ) =EBIT / Enterprise Value (Q: Jan. 2024 )
=-1017.329/-474.1593856
=214.55 %

Zeo ScientifiX's Enterprise Value for the quarter that ended in Jan. 2024 was $-474 Mil.
Zeo ScientifiX's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,017 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zeo ScientifiX EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Zeo ScientifiX's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Zeo ScientifiX (Zeo ScientifiX) Business Description

Traded in Other Exchanges
N/A
Address
3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.
Executives
Skycrest Holdings, Llc 10 percent owner 1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider director, officer: CEO and Director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub officer: Executive Vice President & CSO 23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich officer: COO and Acting CEO 4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser director 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn director 2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz director 58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi director 6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh director E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste director
Ryan C Likes officer: Chief Operating Officer 1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell 10 percent owner, officer: Chief Financial Officer 77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani director, officer: Chief Executive Officer 4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140